Back to top
more

Bolt Biotherapeutics (BOLT)

(Delayed Data from NSDQ)

$0.65 USD

0.65
140,637

-0.01 (-1.58%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $0.64 -0.01 (-1.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gritstone bio (GRTS) delivered earnings and revenue surprises of 38.46% and 66.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2% and 195.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -10.74% and 98.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -26.17% and 57.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 133.33% and 18.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 11.11% and 30.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.52% and 31.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review

by Zacks Equity Research

Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.

Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv

by Zacks Equity Research

Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

by Zacks Equity Research

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

by Zacks Equity Research

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract

by Zacks Equity Research

VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.

Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug

by Zacks Equity Research

Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.

Amylyx (AMLX) Secures the FDA's Approval for ALS Drug

by Zacks Equity Research

Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

by Zacks Equity Research

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity.

Atea (AVIR) Dengue Candidate Gets Fast Track Designation

by Zacks Equity Research

Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

by Zacks Equity Research

Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs

by Zacks Equity Research

Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.

Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent

by Zacks Equity Research

Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.

Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar

by Zacks Equity Research

Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

by Zacks Equity Research

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

by Zacks Equity Research

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.